Articles tagged with Cardiomyopathy
Researchers found that gene silencer therapy may be beneficial for patients with transthyretin amyloid cardiomyopathy, with attenuated benefits observed when combined with TTR stabilizer therapy. The study will be presented at the European Society of Cardiology Congress in Munich, Germany.
Researchers developed a machine learning-based time-to-event model that outperformed existing staging systems in predicting mortality and heart failure hospitalization in transthyretin amyloid cardiomyopathy patients. The model showed promise for individualized prognosis in contemporary clinical care.
Dr. Sebastian Spethmann joins JMIR Cardio as Editor-in-Chief, bringing expertise in heart failure, cardiomyopathies, and digital health. He aims to integrate digital advancements into routine clinical care, enhancing cardiovascular health systems and patient outcomes.
The CARDIO-TTRansform trial investigated eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy, but failed to meet its primary endpoint. The study found that eplontersen reduced circulating serum TTR, but had no significant impact on cardiovascular mortality and recurrent cardiovascular events in the overall popula...
Jeffery Kelly, a Scripps Research professor, has been elected to the European Academy of Engineering for his groundbreaking research on protein folding and its link to diseases. His work led to the development of FDA-approved therapeutics for amyloid polyneuropathy and cardiomyopathy.
Researchers at Murdoch Children's Research Institute have made a breakthrough in gene therapy, restoring heart function in lab-grown patient heart tissue and mouse models with genetic heart disease. The therapy may also correct other genetic heart diseases, including those caused by the MYH7 gene and TTN truncating variants.
The AI model, developed by Mayo Clinic researchers, can identify patients with left ventricular outflow tract obstruction from routine ultrasound videos without relying on specialized Doppler imaging. This technology could help clinicians flag patients with hypertrophic cardiomyopathy who may need additional testing, particularly in se...
Researchers discovered a new mechanism by which leiomodin builds actin filaments in muscles, challenging a long-standing paradigm. This breakthrough may lead to therapies for dilated cardiomyopathy and other muscle diseases.
Researchers have found 17 gene variations in alpha-actinin-2 associated with hypertrophic cardiomyopathy, a leading cause of sudden cardiac death. These variations affect the protein's stability and interactions, highlighting potential targets for new treatments.
Researchers found dapagliflozin significantly reduces risk of heart failure hospitalization in individuals carrying a cardiomyopathy genetic variant. The study, published in Nature Medicine, highlights the potential for incorporating genetic screening into heart failure prevention strategies.
Researchers at Max Delbrück Center uncover a previously unknown genetic mechanism regulating RBM20 protein in heart cells. The discovery reveals multiple transcription start sites for the gene and highlights the importance of isoform balance in disease progression.
A major international study has identified ways to detect patients with hypertrophic cardiomyopathy at serious risk of sudden death, heart failure or other dangerous outcomes. The findings will help save lives by improving the ability to determine who is at greatest risk and spare low-risk patients from unneeded heart implants.
A new model for predicting outcomes in hypertrophic cardiomyopathy has been developed by incorporating prospective data, including clinical history, imaging, and blood biomarker tests. This study found that integrating these methods into risk assessment can improve the prediction of fatal and nonfatal cardiac events.
Researchers are developing a 'heart-on-a-chip' platform with sensors to track cardiac damage and fibrosis in real-time. The project aims to improve the understanding of cardiac involvement in Duchenne muscular dystrophy and speed up treatment evaluation.
High-intensity interval training shows strongest vascular benefits in cardiovascular patients. HIIE consistently improves flow-mediated dilation and vasodilation, with combined high-intensity programs showing the largest estimated effects on endothelial function.
Researchers at Keck School of Medicine have identified a new potential treatment target for AARS2-related cardiomyopathy, a rare and fatal heart muscle disease in infants. By targeting the PCBP1 gene, they aim to restore healthier AARS2 function in heart cells and prevent damage.
Early and continuous acoramidis treatment resulted in sustained incremental reductions in all-cause mortality, cardiovascular-related mortality, and first cardiovascular hospitalization. The findings support the importance of early and continuous long-term treatment with acoramidis in transthyretin amyloid cardiomyopathy.
A global clinical trial led by SickKids has found that mavacamten improves blood flow and reduces obstruction in youth with hypertrophic cardiomyopathy (HCM), a genetic heart disease. The study's results offer hope to families avoiding open-heart surgery, setting the stage for precision therapeutics.
A new study by Cleveland Clinic and Dyania Health demonstrates the potential of large language models in accurately identifying patients who could benefit from clinical research. The AI system reviewed 1,476 patients and identified 46 as potential matches, resulting in a more diverse patient population.
A new study from Uppsala University reveals a substantial increase in cardiomyopathy diagnoses in Sweden between 2004 and 2023, associated with high excess mortality rates. The study highlights the need for improved detection and targeted treatments to address this growing public health concern.
Researchers at University of California San Diego discover gene therapy restoring connexin-43 improves heart function and extends survival in several forms of arrhythmogenic cardiomyopathy. The approach may have broader therapeutic potential across multiple genetic forms of the disease, addressing a critical unmet need.
Researchers have shown that human hearts can regrow muscle cells after a heart attack, paving the way for new treatments to reverse heart failure. The discovery was made possible by pioneering techniques that use living tissue samples taken from patients during bypass surgery.
Researchers at The Lundquist Institute have identified PTRH2 as a critical gene that protects the maternal heart during pregnancy, shedding light on the causes of peripartum cardiomyopathy. Loss of this gene leads to severe postpartum heart failure, highlighting the urgent need for better treatments.
The American Heart Association brought hypertrophic cardiomyopathy and Hands-Only CPR awareness to a historic college football game, aiming to empower young athletes and their families with critical knowledge. The organization aims to double cardiac arrest survival rates by 2030 through its Nation of Lifesavers movement.
A simple echocardiography method analyzes myocardial deformation to predict cardiac complications in chronic Chagas disease. The study found that patients with a greater GLS value had a higher risk of death and complications.
Researchers have found that atrial electromechanical dissociation (AEMD) can predict stroke risk in people with transthyretin amyloid cardiomyopathy, even when the heart rhythm appears normal. A non-invasive assessment tool may help identify those at increased risk and guide earlier conversations about preventive strategies.
A new study from the University of Copenhagen enables researchers to investigate the cause of heart diseases by analyzing thousands of proteins in heart tissue. This groundbreaking method reveals molecular patterns characteristic of heart diseases.
A recent study revealed ROS-induced oxidative stress accelerates hypertrophic cardiomyopathy (HCM) in MYBPC3-deleted hiPSC-CMs. The researchers found that melatonin alleviates HCM by inhibiting the PI3K/AKT/FOXO3a signaling pathways.
Late-breaking clinical trials and science at TCT 2025 will present pivotal data on novel therapies, devices, and techniques aimed at preventing and treating cardiovascular conditions. The symposium delivers high-impact findings that shape clinical practice and enhance outcomes for patients with heart and vascular disease.
A cardiac device trial published in eClinicalMedicine found that improving enrollment of females in such trials can better guide care for all patients. One-year interim study results revealed that participants assigned male at birth were twice as likely to die or experience life-threatening heart rhythm abnormalities, while females sho...
The American College of Cardiology has established a digital registry for hypertrophic cardiomyopathy (HCM) to broaden understanding and provide equitable access to treatment. The registry will capture data on HCM symptoms, diagnostic images, treatment plans, and outcomes to improve diagnosis and management.
Researchers found that individuals with a mutation in the TTN gene are 21 times more likely to develop dilated cardiomyopathy than those without. Lifestyle factors such as being overweight or having high alcohol consumption contribute to an earlier diagnosis, and men with the mutation are more likely to develop DCM at a younger age.
A groundbreaking study published in Science Signaling has identified protein tyrosine phosphatase PTP1B as a key driver of maladaptive cardiac metabolism and dysfunction under dietary stress. Mice lacking PTP1B in cardiomyocytes were resistant to harmful changes, highlighting the enzyme's role in heart disease progression.
Scientists are working on a genetic cure for the world's most common inherited heart disease, hypertrophic cardiomyopathy (HCM), with a new gene editing tool. The team aims to correct mutations that cause the disease, which affects 14 million people worldwide.
Researchers found common variants in TTN and BAG3 associated with reduced late-onset cardiomyopathy in childhood cancer survivors, similar to the general population. However, rare variants linked to early-onset cardiomyopathy in adults showed no association with late-onset risk in children.
Researchers found that MRI scans can detect heart inflammation, scarring, and impaired function in carriers of a mutated LMNA gene. This information can help clinicians predict which patients are at higher risk and inform decisions about treatments such as defibrillators or transplants.
A new AI algorithm, Viz HCM, can quickly and specifically identify high-risk heart patients with hypertrophic cardiomyopathy (HCM) and provide individualized risk assessments. The algorithm's findings can help doctors prioritize the highest-risk patients for earlier appointments and treatment.
A new AI algorithm has been calibrated to quickly identify patients with hypertrophic cardiomyopathy (HCM) and provide individualized risk assessments. The tool can help prioritize high-risk patients for earlier appointments and treatment, leading to better patient outcomes.
A team of researchers has developed a gene-therapy strategy to treat arrhythmogenic right ventricular cardiomyopathy type 5 (ARVC5), a rare and deadly hereditary disease. The treatment, using adeno-associated viruses, improved cardiac function and prolonged survival in mice with ARVC5-like disease.
Preoperative anemia is a recognized risk factor for adverse outcomes in CABG, but it does not affect the long-term survival advantage associated with CABG. This study provides evidence that surgical intervention can still be beneficial for ICM patients despite preoperative anemia.
A study published in Nature Cardiovascular Research found that tricaprin improved long-term survival and recovery from heart failure in patients with triglyceride deposit cardiomyovasculopathy. The supplement reversed structural changes and improved heart muscle function, leading to higher survival rates compared to controls.
A new study identified USP5 as an enzyme crucial for breaking down unneeded or damaged proteins in the heart. Low levels of USP5 lead to protein buildup, triggering dilated cardiomyopathy in animal models. Increasing USP5 levels helps clear protein 'junk', improving heart function and reducing disease progression.
University of Birmingham researchers have been awarded a grant to study the mechanisms driving early cardiac dysfunction in CKD. The study aims to identify interventions that can reverse or prevent heart disease in its earliest stages.
A new study suggests that current guidelines for diagnosing a potentially deadly heart condition may be missing women due to natural differences in sex and body size. The researchers developed a personalized approach using AI, which improved diagnosis accuracy by 20 percentage points for female patients.
Trametinib reduces mortality and morbidity in children with severe HCM caused by pathogenic variants in the RAS/MAPK pathway. The study provides strong evidence for personalized treatment targeting the underlying genetic causes of RASopathies.
The American Heart Association strongly supports the legislation, which aims to double survival rates from cardiac arrest nationwide by 2030. The HEARTS Act includes key provisions such as CPR training, AEDs, and cardiac emergency response plans, which can more than double survival rates in schools with these resources.
Researchers have discovered a potential target to address diabetic cardiomyopathy, a serious condition affecting diabetic patients. The PPARβ/δ receptor's activation can help slow down inflammation and fibrosis, providing a new therapeutic strategy.
The American Heart Association has launched a new three-year initiative to standardize HCM systems of care and support better management of the disease. The initiative aims to overcome gaps in care for hypertrophic cardiomyopathy, leading to delayed treatment, increased risk of complications, and preventable death.
A study by St. Jude Children's Research Hospital has identified a serum protein panel test that accurately predicts cardiomyopathy risk in childhood cancer survivors. The test, using a panel of 27 proteins, was tested on 46 survivors and correctly predicted risk in 38 cases.
A new study has found that hundreds of genes, rather than a single 'aberrant' genetic variant, contribute to the development of dilated cardiomyopathy. Researchers developed a polygenic risk score to assess individual risk and found those with the highest genetic risk had a fourfold chance of developing the disease.
The Heart Institute is celebrated for delivering unparalleled treatment and support to children with heart conditions. It has consistently provided high-quality cardiac care and specialized disease management for all forms of cardiomyopathy.
Patients with transthyretin amyloid cardiomyopathy experience frequent decline in kidney function, associated with higher mortality risk. eGFR decline is an independent marker of disease progression guiding treatment optimization.
New study suggests that small group differences may reflect important benefits for individual patients with cardiomyopathy. The authors recommend explicitly describing patient-level data to support clinical interpretation of results.
The Kansas City Cardiomyopathy Questionnaire (KCCQ) demonstrated strong psychometric properties in patients with severe tricuspid regurgitation. The KCCQ can effectively measure symptoms, function, and quality of life, making it a valuable tool for assessing patient outcomes.
Researchers at the University of Arizona Health Sciences are studying the molecular mechanisms of coagulation factor XII as a contributor to heart failure with reduced ejection. The goal is to develop better preventive and treatment options for this irreversible condition, which affects millions of Americans.
A study at the European Society of Cardiology Congress found that an AI-enabled digital stethoscope helped doctors identify twice as many cases of pregnancy-related heart failure compared to a control group. The tool was 12 times more likely to flag heart pump weakness, leading to better diagnosis and potentially life-saving treatment.
A phase 3 study has shown that vutrisiran, an RNA interference therapeutic, reduces all-cause mortality and recurrent cardiovascular events by 28% and 33% respectively in patients with transthyretin amyloidosis with cardiomyopathy. The treatment also improves functional capacity, quality of life, and NYHA class.
This study identified three novel TTN variants associated with dilated cardiomyopathy in Chinese patients. The variants were found through whole-exome sequencing and are expected to contribute to the disease's molecular mechanisms. The discovery broadens the spectrum of TTN variants and may aid in genetic screening for related diseases.
Researchers used WES to identify a novel deletion variant in the DSP gene associated with sudden cardiac death. This finding highlights the importance of post-mortem genetic testing for accurate risk assessment and personalized medicine.
Researchers at UAB have developed a method to assess cardiac dynamics in fruit flies using deep learning and high-speed video microscopy. The study uses this approach to analyze the effects of aging and dilated cardiomyopathy on heart function, with potential applications for human cardiovascular research.